Skip to main navigation Skip to search Skip to main content

Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine

  • Alison S. Laufer
  • , Jonathan C. Thomas
  • , Marisol Figueira
  • , Janneane F. Gent
  • , Stephen I. Pelton
  • , Melinda M. Pettigrew

Research output: Contribution to journalArticlepeer-review

Abstract

Non-vaccine Streptococcus pneumoniae serotypes are increasingly associated with disease. We evaluated isolates of the same sequence type (ST199) but different serotypes (15B/C, 19A) for growth in vitro, and pathogenic potential in a chinchilla otitis media model. We also developed a quantitative PCR (qPCR) assay to quantitatively assess each isolate, circumventing the need for selectable markers. In vitro studies showed faster growth of serotype 19A over 15B/C. Both were equally capable of colonization and middle ear infection in this model. Serotype 19A is included in new conjugate vaccine formulations while serotype 15B/C is not. Non-capsular vaccine targets will be important in disease prevention efforts.

Original languageEnglish (US)
Pages (from-to)2450-2457
Number of pages8
JournalVaccine
Volume28
Issue number12
DOIs
StatePublished - Mar 11 2010
Externally publishedYes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Conjugate vaccine
  • Streptococcus pneumoniae
  • qPCR assay

Fingerprint

Dive into the research topics of 'Capacity of serotype 19A and 15B/C Streptococcus pneumoniae isolates for experimental otitis media: Implications for the conjugate vaccine'. Together they form a unique fingerprint.

Cite this